Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer’s disease and diabetes mellitus

  • I. Tahirovic
  • E. Sofic
  • A. Sapcanin
  • I. Gavrankapetanovic
  • L. Bach-Rojecky
  • M. Salkovic-Petrisic
  • Z. Lackovic
  • S. Hoyer
  • P. Riederer
Conference paper

DOI: 10.1007/978-3-211-73574-9_29

Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS, volume 72)
Cite this paper as:
Tahirovic I. et al. (2007) Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer’s disease and diabetes mellitus. In: Gerlach M., Deckert J., Double K., Koutsilieri E. (eds) Neuropsychiatric Disorders An Integrative Approach. Journal of Neural Transmission. Supplementa, vol 72. Springer, Vienna

Abstract

It is believed that oxidative stress plays a central role in the pathogenesis of metabolic diseases like diabetes mellitus (DM) and its complications (like peripheral neuropathy) as well as in neurodegenerative disorders like sporadic Alzheimer’s disease (sAD). Representative experimental models of these diseases are streptozotocin (STZ)-induced diabetic rats and STZ-intracerebroventricularly (STZ-icv) treated rats, in which antioxidant capacity against peroxyl (ORAC_roo ) and hydroxyl (ORAC_oh ) free radical was measured in three different brain regions (hippocampus, cerebellum, and brain stem) by means of oxygen radical absorbance capacity (ORAC) assay. In the brain of both STZ-induced diabetic and STZ-icv treated rats decreased antioxidant capacity has been found demonstrating regionally specific distribution. In the diabetic rats these abnormalities were not associated with the development of peripheral diabetic neuropathy. Also, these abnormalities were not prevented by the icv pretreatment of glucose transport inhibitor 5-thio-D-glucose in the STZ-icv treated rats, suggesting different mechanism for STZ-induced central effects from those at the periphery. Similarities in the oxidative stress alterations in the brain of STZ-icv rats and humans with sAD could be useful in the search for new drugs in the treatment of sAD that have antioxidant activity.

Keywords

Rat streptozotocin diabetes mellitus antioxidant capacity oxidative stress 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • I. Tahirovic
    • 1
  • E. Sofic
    • 1
  • A. Sapcanin
    • 1
  • I. Gavrankapetanovic
    • 2
  • L. Bach-Rojecky
    • 3
  • M. Salkovic-Petrisic
    • 4
  • Z. Lackovic
    • 4
  • S. Hoyer
    • 5
  • P. Riederer
    • 6
  1. 1.Department of Chemistry, Faculty of ScienceUniversity of SarajevoSarajevoBosnia and Herzegovina
  2. 2.School of MedicineUniversity of SarajevoSarajevoBosnia and Herzegovina
  3. 3.Department of Pharmacology, School of Pharmacy and BiochemistryUniversity of ZagrebZagrebCroatia
  4. 4.Department of Pharmacology and Croatian Institute for Brain Research, School of MedicineUniversity of ZagrebZagrebCroatia
  5. 5.Department of Pathology, University ClinicUniversity of HeidelbergHeidelbergGermany
  6. 6.Clinical Neurochemistry, Clinic and Policlinic for PsychiatryUniversity of WürzburgWürzburgGermany

Personalised recommendations